Condition
Transplantation, Liver
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
60% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (2)
P 4 (2)
Trial Status
Completed3
Terminated2
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02498977Phase 4TerminatedPrimary
Liver Immunosuppression Free Trial
NCT02356939Not ApplicableTerminatedPrimary
Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation
NCT00117689Phase 2Completed
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
NCT00166556Phase 2CompletedPrimary
A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
NCT00178425Phase 4CompletedPrimary
PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients
Showing all 5 trials